1.Surgical treatment of primary tracheal tumors in 63 cases.
Yan-bin SUN ; Chun-lu YANG ; Hong-xu LIU ; Hou-wen LI ; Yong-xiao HU ; Lin ZHANG ; Shun XU
Chinese Journal of Oncology 2011;33(7):547-549
OBJECTIVETo summarize the experience in diagnosis and treatment of primary tracheal tumors, and to improve the life quality of patients.
METHODSSixty-three patients with primary tracheal tumors treated in the First Affiliated Hospital of China Medical University during the past 40 years were included in this study, among them, there were 42 cases of malignant tumors and 21 cases of benign tumors. The 61 patients underwent surgery including tracheal sleeve resection (22), carinal resection and reconstruction (6), semi-carinal resection and reconstruction (6), tracheal resection for tracheal tumors (17); tracheostomy (4), tracheal resection, partial resection of the thyroid (goiter) and esophagomyotomy (1), tracheal tumor resection and vertical hemilaryngectomy with reconstruction of laryngeal ventricle and trachea by sternocleidomastoid flap (2), cervical trachea and laryngeal resection (1), and carinal scrape (2).
RESULTSFifty-five patients had an uneventful recovery. Eight patients suffered from postoperative complications, among them 3 patients died postoperatively.
CONCLUSIONSPrimary tracheal tumors often present atypical symptoms, are easily misdiagnosed and with poor prognosis. The main aim of treatment remains to remove the airway obstruction.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Adenoid Cystic ; diagnosis ; surgery ; Carcinoma, Squamous Cell ; diagnosis ; surgery ; Chondroma ; diagnosis ; surgery ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Papilloma ; diagnosis ; surgery ; Postoperative Complications ; Reconstructive Surgical Procedures ; methods ; Survival Rate ; Tracheal Neoplasms ; diagnosis ; surgery ; Tracheotomy ; methods ; Young Adult
2. Research progress of MicroRNA in hypertension and its target organ damage
Jing XU ; Qian-Qian CHEN ; Ming-Shuang HOU ; Hong-Ying LYU ; Guan-Jun JIA ; Yu-Shun KOU ; Lin YI ; Jing XU ; Qian-Qian CHEN ; Ming-Shuang HOU ; Hong-Ying LYU ; Guan-Jun JIA ; Yu-Shun KOU ; Lei ZHAO
Chinese Pharmacological Bulletin 2023;39(10):1824-1828
Hypertension is a risk factor for a variety of cardiovascular diseases, which is an important public health problem in the world today. MiRNAs are a class of highly conserved non-coding small RNAs. In recent years, studies have found that miRNAs are involved in the occurrence and development of hypertension through a variety of ways, causing damage to the important target organs of hypertension, such as heart, brain and kidney. This article reviews the research progress of miRNA in hypertension in recent years, in order to clarify its role in the process of hypertension and target organ damage, and provide ideas for exploring new therapeutic targets of hypertension.
3.Potential Clinical Risk of Inflammation and Toxicity from Rare-Earth Nanoparticles in Mice.
Jian-Ping CHEN ; Song-Sheng SHI ; Gui-Fen LIU ; Yan CHEN ; Shui-Shun ZHENG ; Xiao-Bin WANG ; Ru-Hui LIN ; Hong-Xing HE ; Cai-Hou LIN
Chinese Medical Journal 2018;131(13):1591-1597
BackgroundNanotechnology is emerging as a promising tool to perform noninvasive therapy and optical imaging. However, nanomedicine may pose a potential risk of toxicity during in vivo applications. In this study, we aimed to investigate the potential toxicity of rare-earth nanoparticles (RENPs) using mice as models.
MethodsWe synthesized RENPs through a typical co-precipitation method. Institute of Cancer Research (ICR) mice were randomly divided into seven groups including a control group and six experimental groups (10 mice per group). ICR mice were intravenously injected with bare RENPs at a daily dose of 0, 0.5, 1.0, and 1.5 mg/kg for 7 days. To evaluate the toxicity of these nanoparticles in mice, magnetic resonance imaging (MRI) was performed to assess their uptake in mice. In addition, hematological and biochemical analyses were conducted to evaluate any impairment in the organ functions of ICR mice. The analysis of variance (ANOVA) followed by a one-way ANOVA test was used in this study. A repeated measures' analysis was used to determine any significant differences in white blood cell (WBC), alanine aminotransferase (ALT), and creatinine (CREA) levels at different evaluation times in each group.
ResultsWe demonstrated the successful synthesis of two different sizes (10 nm and 100 nm) of RENPs. Their physical properties were characterized by transmission electron microscopy and a 980 nm laser diode. Results of MRI study revealed the distribution and circulation of the RENPs in the liver. In addition, the hematological analysis found an increase of WBCs to (8.69 ± 0.85) × 10/L at the 28 day, which is indicative of inflammation in the mouse treated with 1.5 mg/kg NaYbF:Er nanoparticles. Furthermore, the biochemical analysis indicated increased levels of ALT ([64.20 ± 15.50] U/L) and CREA ([27.80 ± 3.56] μmol/L) at the 28 day, particularly those injected with 1.5 mg/kg NaYbF:Er nanoparticles. These results suggested the physiological and pathological damage caused by these nanoparticles to the organs and tissues of mice, especially to liver and kidney.
ConclusionThe use of bare RENPs may cause possible hepatotoxicity and nephritictoxicity in mice.
4.Advances in Basic Studies on Antitumor Effect and Underlying Molecular Mechanisms of Sinomenine
Lin TANG ; Ye LIN ; Le-ping LIU ; Xiao-shan LU ; Sheng-tao HU ; Er-bing ZHANG ; Feng ZHANG ; Zong-shun DAI ; Hou-pan SONG ; Yu-ming HUANG ; Xiong CAI ; Liang LIU
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(4):175-185
Tumors are new organisms formed by uncontrollable cell proliferation of local tissues driven by various oncogenic factors. The cause of tumors is unknown with life-threating outcome. Tumors can be classified into benign tumors, borderline tumors, and malignant tumors according to their pathological properties. Among them, malignant tumor is commonly known as cancer, with no specific medicines or reliable cure means, so this is a hot spot and difficult point in current medical research. In ancient literatures, there are many records about the efficacy of Chinese herbal medicine in treating tumor, and modern pharmacological researches have shown that more and more active ingredients of traditional Chinese medicine(TCM) have gradually highlighted their inhibitory effect on various types of tumor.
5.Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model.
Cheng CUI ; Miao ZHANG ; Xueting YAO ; Siqi TU ; Zhe HOU ; Valerie Sia JIE EN ; Xiaoqiang XIANG ; Jing LIN ; Ting CAI ; Ning SHEN ; Chunli SONG ; Jie QIAO ; Shun ZHANG ; Haiyan LI ; Dongyang LIU
Acta Pharmaceutica Sinica B 2020;10(7):1216-1227
Chloroquine (CQ) phosphate has been suggested to be clinically effective in the treatment of coronavirus disease 2019 (COVID-19). To develop a physiologically-based pharmacokinetic (PBPK) model for predicting tissue distribution of CQ and apply it to optimize dosage regimens, a PBPK model, with parameterization of drug distribution extrapolated from animal data, was developed to predict human tissue distribution of CQ. The physiological characteristics of time-dependent accumulation was mimicked through an active transport mechanism. Several dosing regimens were proposed based on PBPK simulation combined with known clinical exposure-response relationships. The model was also validated by clinical data from Chinese patients with COVID-19. The novel PBPK model allows in-depth description of the pharmacokinetics of CQ in several key organs (lung, heart, liver, and kidney), and was applied to design dosing strategies in patients with acute COVID-19 (Day 1: 750 mg BID, Days 2-5: 500 mg BID, CQ phosphate), patients with moderate COVID-19 (Day 1: 750 mg and 500 mg, Days 2-3: 500 mg BID, Days 4-5: 250 mg BID, CQ phosphate), and other vulnerable populations (.., renal and hepatic impairment and elderly patients, Days 1-5: 250 mg BID, CQ phosphate). A PBPK model of CQ was successfully developed to optimize dosage regimens for patients with COVID-19.
6.A rapid colloidal gold immunochromatographic assay for the diagnosis of coronavirus disease 2019.
Xiao-Ling WANG ; Lei WANG ; Chao-Lu HASI ; Yu-Po WANG ; Ajab KHAN ; Bin-Zhi REN ; Zhi-Zhen LIU ; Shun-Lin HOU ; Li-Hong YANG ; Liao-Yun ZHANG ; Yong-Kang DONG ; Jun XU ; Jun XIE
Chinese Medical Journal 2020;133(16):1986-1988